About Cronos

Cronos Clinical Consulting Services, Inc. is a leading global provider of specialty clinical service solutions that combine science, technology, and innovation.

For over 10 years, Cronos has demonstrated commitment to ensuring quality in clinical trials, with a focus on applying custom solutions to meet the unique challenges of our clients. Our proven solutions have resulted in demonstrable benefits to our clients, such as the ability to make evidence-based decisions regarding site and rater actions (e.g., removal, initiation of a site visit), increased data integrity, and decreased financial burden.

Real-time Analytics

Our extensive risk-based monitoring (RBM) database allows us to proactively assess for potential risk prior to study initiation. These areas of risk may be mitigated by appropriate rater training and institution of in-study RBM algorithms to identify issues and allow for them to be addressed in real-time.

Evidence-based Design

In the event that a trial is in process or has already concluded, Cronos retrospective analyses evaluate the degree of confidence that may be placed in the data obtained. Detailed reports identify specific data issues and recommendations to minimize related risk in future studies.

Operational Excellence

All of our service solutions are delivered with operational excellence, which may be further enhanced by our Cronos Integrated Research Platform (CIRP) that simplifies scheduling, tracking and communication among all study vendors and resources.

Collaborations

We're proud to have partnered with these great institutions

Expertise

Cronos has worked in over 50 countries includingArgentina, Australia, Belgium, Bulgaria, Canada, China, Columbia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Italy, Japan, Malaysia, Mexico, New Zealand, Norway, Philippines, Poland, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine, United Kingdom, and United States.

Cronos has extensive experience supporting clinical trials research in psychotic disorders, mood disorders, movement disorders, neurodegenerative disorders, and developmental disorders. The assessment instruments utilized have included, but are not limited to, the following: Positive and Negative Syndrome Scale for Schizophrenia (PANSS), Negative Symptom Assessment-16 item (NSA-16), Matrics Consensus Cognitive Battery (MCCB), Montgomery-Åsberg Depression Rating Scale (MADRS), Hamilton Depression Rating Scale (HAM-D), Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Clinical Dementia Rating Scale (CDRS), Neuropsychological Test Battery (NTB), Young Mania Rating Scale (YMRS), Clinical Global Impression–Severity/Improvement (CGI-S/CGI-I), Autism Diagnostic Interview-Revised (ADI-R), Unified Parkinson’s Disease Rating Scale (UPDRS), Yale Global Tic Severity Scale (YGTSS).

Additionally, numerous patient reported outcome measures have been implemented into our training and risk-based data monitoring programs.